PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance

PURPOSE: To investigate the clinical relevance of PTEN in HER2-amplified and HER2-non-amplified disease. EXPERIMENTAL DESIGN: We assessed PTEN status in two large adjuvant breast cancer trials (BCIRG-006 and BCIRG-005) using a PTEN IHC assay that was previously validated in a panel of 33 breast canc...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Stern, Howard M., Gardner, Humphrey, Burzykowski, Tomasz, Elatre, Wafaa, O’Brien, Carol, Lackner, Mark R., Pestano, Gary A., Santiago, Angela, Villalobos, Ivonne, Eiermann, Wolfgang, Pienkowski, Tadeusz, Martin, Miguel, Robert, Nicholas, Crown, John, Nuciforo, Paolo, Bee, Valerie, Mackey, John, Slamon, Dennis J., Press, Michael F.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4417419/
https://ncbi.nlm.nih.gov/pubmed/25649019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2993
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller